© Georg Thieme Verlag KG Stuttgart · New York
Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive-Aggressive Symptoms during Risperidone Therapy
10 December 2009 (online)
Introduction: The aim of this prospective naturalistic study was to examine for the first time the relationship between dosage, serum concentration and clinical outcome in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.
Methods: Steady state trough serum concentrations of risperidone and 9-hydroxyrisperidone (the active moiety) were measured in 103 subjects. The therapeutic effect was assessed by the clinical global impression improvement subscale and side effects by the Udvalg for Kliniske Undersogelser-side effect rating scale.
Results: We found a linear relationship between the risperidone dose and the serum concentration of the active moiety (Spearman ρ=0.53) and no correlation between the serum concentration and either the therapeutic effect or side effects. There was no effect of gender and co-medication.
Discussion: This study has the typical limitations of naturalistic studies, therefore our results should be interpreted with caution. Based on the serum concentrations at the therapeutically effective dose range (0.25–1.5 mg/day) we obtained first information on a possibly appropriate therapeutic serum range for the risperidone treatment of children and adolescents with impulsive-aggressive symptoms. Further studies with greater sample sizes are needed to validate our results and to examine the influence of genetic polymorphisms on the serum concentration of risperidone.
- 1 Aman MG, Tassé MJ, Rojahn J. et al . The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities. 1996; 17 41-57
- 2 Aman MG, De Smedt G, Derivan A. et al . Risperidone Disruptive Behavior Study Group Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002; 159 1337-1346
- 3 Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004; 14 243-254
Diagnostic and Statistical Manual of Mental Disorders. 4th Edition (DSM-IV), Washington DC, APA 1994
- 5 Aravagiri M, Marder SR, Wirshing D. et al . Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 1998; 31 102-109
- 6 Aravagiri M, Marder SR, Nuechterlein KH. et al . Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003; 25 657-664
- 7 Baumann P, Hiemke C, Ulrich S. et al . The AGNP-TDM expert group consensus guidelines. Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004; 37 243-265
- 8 Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006; 39 10-14
- 9 Clement HW, Taram C, Fleischhaker C. et al .
Bestimmung und Wirkung der Höhe des Serumspeigels von Risperidon und 9-Hydroxyrisperidon in einem Kollektiv von Kindern und Jugendlichen. In: Schulte-Markwort M, editor Psychosomatik- Kinder- und Jugendpsychiatrie als interdisziplinäres Fach, Medizinisch Wissenschaftliche Verlagsgesellschaft 2009
- 10 De Leon J, Susce MT, Pan RM. et al . A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007; 40 93-102
- 11 Farde L, Nordström AL, Wiesel FA. et al . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49 538-544
- 12 Findling RL, McNamara NK, Branicky LA. et al . A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000; 39 509-516
- 13 Findling RL. Dosing of atypical antipsychotics in children and adolescents. Primary Care Companion J Clin Psychiatry. 2003; 5 10-13
- 14 Findling RL. Atypical antipsychotic treatment of disruptive behaviour disorders in children and adolescents. J Clin Psychiatry. 2008; 69 9-14
- 15 Gerlach M, Rothenhöfer S, Mehler-Wex C. et al . Therapeutic drug monitoring in child and adolescent psychiatry practical recommendations. Z Kinder Jugendpsychiatr Psychother. 2006; 34 5-13
- 16 Gründer G, Fellows C, Janouschek H. et al . Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry. 2008; 165 988-995
- 17 Guy W.
ECDEU assessment manual. Rockville, National Institute of Mental Health 1976
- 18 Heykants J, Huang ML, Mannens G. et al . The pharmacokinetics of risperidone in humans: A summary. J Clin Psychiatry. 1994; 55 13-17
- 19 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156 286-293
- 20 Kirschbaum KM, Finger S, Vogel F. et al . High performance-liquid chromatography with column-switching and spectro–photometric detection for determination of risperidone and 9-hydroxyrisperidone in human serum. Chromatographia. 2008; 67 321-324
- 21 Lingjaerde O, Ahlfors UG, Bech P. et al . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987; 334 1-100
- 22 Maughan B, Rowe R, Messer J. et al . Conduct disorder and oppositional defiant disorder in a national sample: Developmental epidemiology. J Child Psychol Psychiatry. 2004; 45 609-621
- 23 Mauri MC, Volonteri LS, Colasanti A. et al . Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46 359-388
- 24 McCracken JT, McGough J, Shah B. et al . Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002; 347 314-321
- 25 Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res. 2006; 10 167-179
- 26 Mehler-Wex C, Kölch M, Kirchheiner J. et al . Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child and AdolescPsychiatry Ment Health. 2009; 3 14
- 27 Nock MK, Kazdin AE, Hiripi E. et al . Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: Results from the National Comorbidity Survey Replication. J Child Psychol Psychiatry. 2007; 48 703-713
- 28 Olesen O, Licht R, Thomsen E. et al . Serum concentrations and side effects in psychiatric patients during risperidone therapy. Therapeutic Drug Monitoring. 1998; 20 380-384
- 29 Pappadopulos E, Woolston S, Chait A. et al . Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. Can Acad Child Adolesc Psychiatry. 2006; 15 27-39
- 30 Ricci LA, Connor DF, Morrison R. et al . Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. Biol Psychiatry. 2007; 62 218-225
- 31 Schwartzer JJ, Connor DF, Morrison RL. et al . Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. Physiol Behav. 2008; 95 176-181
- 32 Snyder R, Turgay A, Aman M. et al . Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002; 41 1026-1036
- 33 Turgay A, Binder C, Snyder R. et al . Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs. Pediatrics. 2002; 110 34
Dr. med. K. Klampfl
Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy
University of Wuerzburg
Phone: +49/931/201 78010
Fax: +49/931/201 78040